NEJM Journal Watch Oncology and Hematology Top Stories of 2018

This year, our list of NEJM Journal Watch Oncology and Hematology top stories includes studies on breast, prostate, lung, and colon cancer as well as malignant and benign hematology. These summaries underscore our goal of identifying the most clinically relevant studies and highlighting their key findings and implications. We look forward to continuing to bring you concise summaries of the most important research in oncology and hematology during the coming year.

Our oncology and hematology top 10 stories of 2018 are as follows:

• Immunotherapy for Breast Cancer Has Arrived

• Fewer Patients with Breast Cancer Require Chemotherapy

• Enzalutamide for Castration-Resistant PSA-Only Prostate Cancer

• Apalutamide for Castration-Resistant PSA-Only Prostate Cancer

• Front-Line Therapy for Extensive-Stage, Small Cell Lung Cancer: A New Standard

• First-Line Nivolumab plus Ipilimumab for Advanced Non–Small-Cell Lung Cancer

• Shorter Duration Adjuvant Therapy for Stage III Colon Cancer

• Nivolumab plus Ipilimumab for Advanced Renal-Cell Carcinoma

• Front-Line Immunotherapy for Myeloma

• Gene Therapy for Factor IX Deficiency Hemophilia